Ignite Creation Date:
2024-05-05 @ 5:07 PM
Last Modification Date:
2024-10-26 @ 9:28 AM
Study NCT ID:
NCT00390416
Status:
COMPLETED
Last Update Posted:
2016-03-14
First Post:
2006-10-17
Brief Title:
Study of Docetaxel Cisplatin and Fluorouracil Modified DCF With Bevacizumab in Patients With Unresectable or Metastatic Gastroesophageal Adenocarcinoma
Sponsor:
Memorial Sloan Kettering Cancer Center
Organization:
Memorial Sloan Kettering Cancer Center
Study Overview
Official Title:
A Phase II Study of Docetaxel Cisplatin and Fluorouracil Modified DCF With Bevacizumab in Patients With Unresectable or Metastatic Gastroesophageal Adenocarcinoma
Status:
COMPLETED
Status Verified Date:
2016-02
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This study is being done to find out what effects a drug namedcalled bevacizumab has on patients and patients tumors when given together with standard chemotherapy drugs Making new blood vessels seems to be important for many tumors to grow Bevacizumab is a new type of treatment for cancer that blocks the growth of new tumor blood vessels In this study the researchers will combine bevacizumab with chemotherapy drugs that are standard for the patients disease and include cisplatin docetaxel fluorouracil and leucovorin The way the original combination of cisplatin docetaxel and fluorouracil was given caused many side effects including gastrointestinal symptoms weakness and a drop in the blood count of infection fighting cells For this study the researchers have modified this combination to give lower doses of the medicines more often to reduce side effects from the chemotherapy Patients will receive bevacizumab with this modified combination of docetaxel cisplatin and fluorouracil This study is called a phase II study In this study everyone will have similar tumors and receive the same treatment
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None